Tudor Investment Corp ET AL Invests $560,000 in Collegium Pharmaceutical, Inc. $COLL

Tudor Investment Corp ET AL purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, HoldingsChannel reports. The firm purchased 16,010 shares of the specialty pharmaceutical company’s stock, valued at approximately $560,000.

A number of other large investors also recently bought and sold shares of the business. Millennium Management LLC boosted its position in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after buying an additional 242,310 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in shares of Collegium Pharmaceutical by 237.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after buying an additional 225,679 shares during the period. Voloridge Investment Management LLC raised its stake in shares of Collegium Pharmaceutical by 854.2% during the 3rd quarter. Voloridge Investment Management LLC now owns 249,473 shares of the specialty pharmaceutical company’s stock worth $8,729,000 after buying an additional 223,329 shares during the period. Finally, Amundi purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at approximately $6,276,000.

Collegium Pharmaceutical Trading Up 3.4%

Shares of COLL opened at $33.07 on Wednesday. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $50.79. The stock has a market cap of $1.05 billion, a PE ratio of 19.34 and a beta of 0.67. The firm’s fifty day moving average is $41.35 and its two-hundred day moving average is $41.66. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The business had revenue of $205.45 million during the quarter, compared to analysts’ expectations of $206.36 million. Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period last year, the business earned $1.77 earnings per share. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the transaction, the executive vice president owned 71,770 shares in the company, valued at approximately $2,900,225.70. This trade represents a 41.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP David Dieter sold 13,976 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 2.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Barclays dropped their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research report on Friday, January 9th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $53.40.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.